

Specialty Pharmacy Program

Ampyra™ (dalfampridine)

DESCRIPTION

Ampyra is a potassium channel blocker indicated to improve walking speed in patients with multiple sclerosis.

APPROVAL DURATION

Initial therapy: 3 months

Maintenance therapy: 1 year

APPROVAL CRITERIA

Ampyra will be approved if the patient meets the following criteria:

- I. Patient has diagnosis of multiple sclerosis (MS) **AND**
- II. Patient does not have a history of seizures **AND**
- III. Patient does not have moderate or severe renal impairment (CrCl \leq 50 mL/min) **AND**
- IV. Patient has sustained walking impairment but does not require a wheelchair for mobility **AND**
- V. Patient has had a timed 25-foot walk (T25FW) test evaluated before treatment, at least 3 months after initiation of therapy, and while on therapy **AND**
- VI. Patient must demonstrate an improvement in T25FW test results relative to pre-treatment results for renewals **AND**
- VII. The prescribed dose does not exceed 10 mg twice daily.